@resatcinar profile picture
RESAT CINAR @resatcinar

Scientist, pharmacist, pharmacologist, researching on cannabinoids, endocannabinoids, and pulmonary fibrosis. fibrosis researcher. —opinions are my own views.

Joined July 2012
  • Tweets 113
  • Following 141
  • Followers 155
22 Photos and videos
🚀 Postdoc Opportunity in Systems Biology @NIH (NIAAA) Join our collaborative team studying fibrosis using cutting-edge multi-omics & spatial biology approaches. 📍 Bethesda, MD, USA 
🔗 training.nih.gov/jobs/pd-080… #Postdoc #Bioinformatics #SystemsBiology #Omics #NIH

Postdoctoral Fellow

training.nih.gov
10
21
2,007
RESAT CINAR retweeted
Ozge Gunduz-Cinar@gunduzozge
5 Dec 2025
1/4 New Paper 🧠🐭 #Neuroscience #Dopamine #FearExtinction #eNeuro Altered Dopamine Signaling in Extinction-Deficient Mice eneuro.org/content/12/11/ENE…

Altered Dopamine Signaling in Extinction-Deficient Mice

A central mechanism of exposure-based cognitive behavioral therapy for anxiety and trauma-related disorders is fear extinction. However, the mechanisms underlying fear extinction are deficient in...

eneuro.org
3
2
10
1,043
✨Exciting to see clinical efficacy of peripheral #CB1R antagonism with #monlunabant. It will expand armamentarium for #obesity with a different mechanism than incretins (#GLP1 #GIP) ⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
The Lancet Diabetes & Endocrinology@TheLancetEndo
5 Oct 2025
Efficacy and safety of #monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial thelancet.com/journals/landi… #obesity #MetabolicSyndrome
(A) Estimated change in bodyweight from baseline to week 16 (95% CI). Overall mean baseline bodyweight was 110·1 kg. The estimated treatment differences with 95% CIs are noted for each monlunabant group compared with the placebo group. (B) Observed mean change (SEM) in bodyweight (kg) for each group over time. Numbers shown in the lower panel are number of participants contributing to the mean.

ALT (A) Estimated change in bodyweight from baseline to week 16 (95% CI). Overall mean baseline bodyweight was 110·1 kg. The estimated treatment differences with 95% CIs are noted for each monlunabant group compared with the placebo group. (B) Observed mean change (SEM) in bodyweight (kg) for each group over time. Numbers shown in the lower panel are number of participants contributing to the mean.
1
4
196
📣Our research @JCI_Insight highlights the key role of #cannabinoid receptor 1 (#CB1R) in #AlveolarMacrophages in promoting #PulmonaryFibrosis. We propose that pulmonary delivery of #zevaquanabant as an effective and safer therapeutic approach for PF insight.jci.org/articles/vie…
3
5
20
1,240
more replies
🧵6️⃣ 📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS). 📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
1
3
105
🧵7️⃣ Our research exemplifies amazing team and collaborative effort (@m_konigshoff lab)! Big shout out to @abhishekbasu86 @muharif #antifibrotic #TherapeuticDiscovery #DrugDiscovery #PulmonaryFibrosis #CurePF #CureHPS #CB1R
4
72
‼️A post-doc position available in my lab at the NIH ‼️ ⚡️Fibrosis Biology ⚡️Biomarker Discovery ⚡️Pharmacology ⚡️Therapeutic discovery ⚡️Translational research See the position details👇 training.nih.gov/jobs/pdf-09… #postdoc #Fibrosis #pulmonaryfibrosis #RareDisease Please RT
11
19
2,515
Our research shows anandamide in blood has biomarker functions in Hermansky-Pudlak syndrome. It not only captures early stage fibrosis progression in lung but also informs on therapeutic effect for CB1R antagonism.This may help to design effective anti-fibrotic therapy @CureHPS
ATS Blue Journal@ATSBlueEditor
18 Apr 2025
Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis This study suggests that circulating anandamide levels begin to increase with the fibrotic lung process even at subclinical stages @resatcinar @IRPatNIH 🔗 tinyurl.com/2p9nrru7
4
170
RESAT CINAR retweeted
Yasmin Hurd, PhD@neurovoice
18 Feb 2025
📣 New Hurd Lab paper in @molpsychiatry explores how cannabidiol (#CBD) can help reduce anxiety linked to specific triggers. Learn more about our findings 🧵 and read the full paper: nature.com/articles/s41380-0… (1/7)
1
12
39
2,092
Congrats to @pommerollelenny and @ctm_dijon team for this impactful work! This work not only endorsed CD206 expressing macrophages as a profibrotic macrophages in progressive #pulmonaryfibrosis but also elegantly provides an imaging tool to use biomarker function of CD206 imaging
This tweet is unavailable
4
258
Our preprint presents #endocannabinoid #anandamide (#CB1R agonist) in blood has both early disease #biomarker and surrogate marker functions in Hermansky Pudlak syndrome pulmonary #fibrosis (#HPSPF) @HPSNetwork
medRxiv@medrxivpreprint
18 May 2024
Anandamide is an Early Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis medrxiv.org/cgi/content/shor… #medRxiv
1
1
2
299
more replies
#CB1R antagonism reversed circulating #AEA in serum and attenuated progression of pulmonary fibrosis in the experimental model of HpsPF.
1
1
105
The blood biomarker functions of #Anandamide may help targeted prophylactic or early therapeutic interventions in a highly predictable fibrosing #rarelungdisease #HPSPF in the future.
92
Load more